The drug pipeline of Priavoid is composed of 6 development programs for 5 CNS diseases:

  • Alzheimer’s disease
  • Neuropathic pain
  • Amyotrophic lateral sclerosis
  • Tauopathies
  • Parkinson’s disease
all-D-Peptide Pipeline



is the most advanced drug in our pipeline for the causal treatment of Alzheimer’s disease (AD).


Thus, PRI-002 has three unique selling propositions (USPs):


New mechanism of action
Specific elimination of toxic Aβ oligomers

New drug substance class
Synthetic all-D-peptide

Oral drug administration
Protease resistant

Intervention Strategy

Intervention Strategy

Priavoid developed a completely new therapeutic strategy for the causal treatment of Alzheimer’s disease.  The orally available D-peptide PRI-002  permeates the blood-brain barrier effectively, does not interfere with formation or clearance of non-toxic Aß monomers, but specifically eliminates cytotoxic  Aß-oligomers.



Partnering is a key component of Priavoids strategy